Abingworth LLP E Ffector Therapeutics, Inc. Transaction History

Abingworth LLP

  • $301 Million
  • Q4 2022

A detailed history of Abingworth LLP transactions in E Ffector Therapeutics, Inc. stock. As of the latest transaction made, Abingworth LLP holds 4,822,114 shares of EFTR stock, worth $0. This represents 0.69% of its overall portfolio holdings.

Number of Shares
4,822,114
Previous 4,822,114 -0.0%
Holding current value
$0
Previous $2.73 Million 24.07%
% of portfolio
0.69%
Previous 0.93%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
BUY
$8.56 - $27.17 $41.3 Million - $131 Million
4,822,114 New
4,822,114 $67 Million

Others Institutions Holding EFTR

# of Institutions
5
Shares Held
6.46M
Call Options Held
0
Put Options Held
0
View Full List

About eFFECTOR Therapeutics, Inc.

EFTR Quotes by TradingView
  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Abingworth LLP Portfolio

Follow Abingworth LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abingworth LLP, based on Form 13F filings with the SEC.

News

Stay updated on Abingworth LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email